ABSTRACT
BACKGROUND: Gleditsiae Sinensis Fructus (GSF) is commonly used in traditional medicine to treat respiratory diseases such as bronchial asthma. However, there is a lack of research on the chemical composition of GSF and the pharmacological substance and mechanism of action for GSF in treating bronchial asthma. PURPOSE: The chemical constituents of GSF were analyzed using ultrahigh-performance liquid chromatography-quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS). In this study, we combined network pharmacology, molecular docking techniques, and experimental validation to explore the therapeutic efficacy and underlying mechanism of GSF in the treatment of bronchial asthma. METHODS: Characterization of the chemical constituents of GSF was conducted using UHPLC-Q-Orbitrap HRMS. The identified chemical components were subjected to screening for active ingredients in the Swiss Absorption, Distribution, Metabolism, and Excretion (ADME) database. Relevant databases were utilized to retrieve target proteins for the active ingredients and targets associated with bronchial asthma disease, and the common targets between the two were selected. Subsequently, the protein-protein interaction (PPI) network was constructed using the String database and Cytoscape software to identify key targets. Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using the Metascape database. The "component-common target" network was constructed using Cytoscape to identify the primary active ingredients. Molecular docking validation was conducted using AutoDock software. The bronchial asthma mouse model was established using ovalbumin (OVA), and the lung organ index of the mice was measured. Lung tissue pathological changes were observed using hematoxylin and eosin (HE), Periodic Acid-Schiff (PAS), and Masson staining. The respiratory resistance (Penh) of the mice was assessed using a pulmonary function test instrument. An enzyme-linked immunosorbent assay (ELISA) was used to determine the levels of IgE, IL-4, IL-5, and IL-13 in the mouse serum. Immunofluorescence staining was performed to detect the protein expression levels of AKT and PI3K in the lung tissues. An in vitro experiment was performed to observe the effects of echinocystic acid (EA) on IL-4 stimulated Human ASMCs (hASMCs). Cell viability was measured using a CCK-8 assay to calculate the IC50 value of the EA. A wound healing test was conducted to observe the effect of EA on degree of healing. RT-qPCR was performed to detect the influence of EA on the mRNA expression levels of ALB, SRC, TNF-α, AKT1, and IL6 in the cells. RESULTS: A total of 95 chemical constituents were identified from the GSF. Of these, 37 were identified as active ingredients. There were 169 overlapping targets between the active ingredients and the disease targets. A topological analysis of the protein-protein interaction (PPI) network identified the core targets as IL6, TNF, ALB, AKT1, and SRC. An enrichment analysis revealed that the treatment of bronchial asthma with GSF primarily involved the AGE-RAGE signaling pathway and the PI3K-Akt signaling pathway, among others. The primary active ingredients included 13(s)-HOTRE, linolenic acid, and acacetin. The molecular docking results demonstrated a favorable binding activity between the critical components of GSF and the core targets. Animal experimental studies indicated that GSF effectively improved symptoms, lung function, and lung tissue pathological changes in the OVA-induced asthmatic mice, while alleviating inflammatory responses. GSF decreased the fluorescent intensity of the AKT and PI3K proteins. The IC50 value of EA was 30.02µg/ml. EA (30) significantly promoted the proliferation of IL4-stimulated hASMCs cells. EA (30) significantly increased the expression of ALB and SRC mRNA and decreased the expressions of TNF-α, AKT, and IL6 mRNA. CONCLUSION: The multiple active ingredients found in GSF exerted their anti-inflammatory effects through multiple targets and pathways. This preliminary study revealed the core target and the mechanism of action underlying its treatment of bronchial asthma. These findings provided valuable insights for further research on the pharmacological substances and quality control of GSF.
Subject(s)
Asthma , Drugs, Chinese Herbal , Molecular Docking Simulation , Animals , Asthma/drug therapy , Drugs, Chinese Herbal/pharmacology , Drugs, Chinese Herbal/chemistry , Mice , Anti-Asthmatic Agents/pharmacology , Mice, Inbred BALB C , Bronchitis/drug therapy , Network Pharmacology , Protein Interaction Maps , Ovalbumin , Fruit/chemistry , Chromatography, High Pressure Liquid/methods , Humans , Disease Models, Animal , MaleABSTRACT
BACKGROUND: Although quercetin exhibits promising anti-tumor properties, its clinical application is limited due to inherent defects and a lack of tumor targeting. OBJECTIVE: This study aimed to prepare and characterize active targeting folate-chitosan modified quercetin liposomes (FA-CS-QUE-Lip), and its antitumor activity in vitro and in vivo was also studied. METHODS: Box-Behnken Design (BBD) response surface method was used to select the optimal formulation of quercetin liposomes (QUE-LP). On this basis, FA-CS-QUE-LP was obtained by connecting folic acid chitosan complex (FA-CS) and QUE-LP. The release characteristics in vitro of QUE-LP and FA-CS-QUE-LP were studied. Its inhibitory effects on HepG2 cells were studied by the MTT method. The pharmacokinetics and pharmacodynamics in vivo were studied in healthy Wistar mice and S180 tumor-bearing mice, respectively. RESULTS: The average particle size, zeta potential and encapsulation efficiency of FA-CS-QUELP were 261.6±8.5 nm, 22.3±1.7 mV, and 98.63±1.28 %, respectively. FA-CS-QUE-LP had a sustained release effect and conformed to the Maloid-Banakar release model (R2=0.9967). The results showed that FA-CS-QUE-LP had higher inhibition rates on HepG2 cells than QUE-Sol (P<0.01). There was a significant difference in AUC, t1/2, CL and other pharmacokinetic parameters among QUE-LP, FA-CS-QUE-LP, and QUE-Sol (P<0.05). In in vivo antitumor activity study, the weight inhibition rate and volume inhibition rate of FA-CS-QUE-LP were 30.26% and 37.35%, respectively. CONCLUSION: FA-CS-QUE-LP exhibited a significant inhibitory effect on HepG2 cells, influenced the pharmacokinetics of quercetin in mice, and demonstrated a certain inhibitory effect on S180 tumor-bearing mice, thus offering novel avenues for cancer treatment.
ABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Acute lung injury (ALI) is one of the fatal complications of respiratory virus infections such as influenza virus and coronavirus, which has high clinical morbidity and mortality. Jinhua Qinggan granules (JHQG) has been approved by China Food and Drug Administration in the treatment of H1N1 influenza and mild or moderate novel coronavirus disease 2019 (COVID-19), which is an herbal formula developed based on Maxingshigan decoction and Yinqiao powder that have been used to respiratory diseases in China for thousands of years. However, the underlying mechanism of JHQG in treating infectious diseases remains unclear. AIM OF THE STUDY: This study investigated the effects of JHQG on neutrophil apoptosis and key signaling pathways in lipopolysaccharide (LPS) -induced ALI mice in order to explore its mechanism of anti-inflammation. MATERIALS AND METHODS: The effect of JHQG on survival rate was observed in septic mouse model by intraperitoneal injection of LPS (20 mg/kg). To better pharmacological evaluation, the mice received an intratracheal injection of 5 mg/kg LPS. Lung histopathological changes, wet-to-dry ratio of the lungs, and MPO activity in the lungs and total protein concentration, total cells number, TNF-α, IL-1ß, IL-6, and MIP-2 levels in BALF were assessed. Neutrophil apoptosis rate was detected by Ly6G-APC/Annexin V-FITC staining. Key proteins associated with apoptosis including caspase 3/7 activity, Bcl-xL and Mcl-1 were measured by flow cytometry and confocal microscope, respectively. TLR4 receptor and its downstream signaling were analyzed by Western blot assay and immunofluorescence, respectively. RESULTS: JHQG treatment at either 6 or 12 g/kg/day resulted in 20% increase of survival in 20 mg/kg LPS-induced mice. In the model of 5 mg/kg LPS-induced mice, JHQG obviously decreased the total protein concentration in BALF, wet-to-dry ratio of the lungs, and lung histological damage. It also attenuated the MPO activity and the proportion of Ly6G staining positive neutrophils in the lungs, as well as the MIP-2 levels in BALF were reduced. JHQG inhibited the expression of Mcl-1 and Bcl-xL and enhanced caspase-3/7 activity, indicating that JHQG partially acted in promoting neutrophil apoptosis via intrinsic mitochondrial apoptotic pathway. The levels of TNF-α, IL-1ß, and IL-6 were significantly declined in LPS-induced mice treated with JHQG. Furthermore, JHQG reduced the protein expression of TLR4, MyD88, p-p65 and the proportion of nuclei p65, suggesting that JHQG treatment inhibited TLR4/MyD88/NF-κB pathway. CONCLUSION: JHQG reduced pulmonary inflammation and protected mice from LPS-induced ALI by promoting neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway, suggesting that JHQG may be a promising drug for treatment of ALI.
Subject(s)
Acute Lung Injury , COVID-19 , Influenza A Virus, H1N1 Subtype , Mice , Animals , NF-kappa B/metabolism , Toll-Like Receptor 4/metabolism , Lipopolysaccharides/toxicity , Myeloid Differentiation Factor 88/metabolism , Neutrophils , Tumor Necrosis Factor-alpha/metabolism , Influenza A Virus, H1N1 Subtype/metabolism , Interleukin-6/metabolism , Myeloid Cell Leukemia Sequence 1 Protein/metabolism , Myeloid Cell Leukemia Sequence 1 Protein/therapeutic use , Acute Lung Injury/chemically induced , Acute Lung Injury/drug therapy , Acute Lung Injury/metabolism , ApoptosisABSTRACT
To investigate the effect of Rehmanniae Radix on depression-like behavior and monoamine neurotransmitters of chronic unpredictable mild stress(CUMS) model rats. CUMS combined with isolated feeding was used to induce the depression model of rats. The depression-like behavior of rats was evaluated by sucrose preference test, open field test, and forced swim test. Hematoxylin-Eosin(HE) staining was used to investigate the pathological changes of neurons in the CA1 and CA3 area of hippocampus. Ultra performance liquid chromatography-tandem mass spectrometry(UPLC-MS) was used to detect the contents of 5-hydroxytryptamine(5-HT), 5-hydroxyindoleacetic acid(5-HIAA), dopamine(DA), 3,4-dihydroxyphenylacetic acid(DOPAC), homovanillic acid(HVA), norepinephrine(NE), and 3-methoxy-4-hydroxyphenyl glycol(MHPG) in rats. Western blot was used to detect the protein expressions of tryptophan hydroxylase 2(TPH2), serotonin transporter(SERT), and monoamine oxidase A(MAO-A) in the hippocampus of rats. Compared with the normal group, depressive-like behavior of rats was obvious in the model group. The arrangements of neurons in the CA1 and CA3 area of hippocampus were loose and disorderly. The levels of 5-HT, 5-HIAA, and 5-HT/5-HIAA in the hippocampal area were decreased(P<0.01). The protein expression of TPH2 was decreased(P<0.01), but those of SERT and MAO-A were increased(P<0.01). In the Rehmanniae Radix groups with 1.8 g·kg~(-1) and 7.2 g·kg~(-1), the depression-like behavior of CUMS rats and pathological changes of neurons in CA1, CA3 area of hippocampus were improved. The protein expression of TPH2(P<0.05, P<0.01) was increased, and those of SERT and MAO-A were down-regulated(P<0.05, P<0.01). The levels of 5-HT, 5-HIAA, and 5-HT/5-HIAA in hippocampus were increased(P<0.05, P<0.01). The changes in DA, DOPAC, HVA, DA/(DOPAC +HVA), NE, DHPG, and NE/DHPG were not statistically significant. The results suggested that Rehmanniae Radix improved depression-like behavior of CUMS rats, and the mechanism might be related to the regulation of synthesis, transportation, and metabolism of 5-HT neurotransmitter in the hippocampus.
Subject(s)
Antidepressive Agents , Depression , Hippocampus , Hydroxyindoleacetic Acid , Rehmannia , Serotonin , 3,4-Dihydroxyphenylacetic Acid/metabolism , 3,4-Dihydroxyphenylacetic Acid/pharmacology , Animals , Antidepressive Agents/pharmacology , Antidepressive Agents/therapeutic use , Chromatography, Liquid , Depression/drug therapy , Disease Models, Animal , Dopamine , Eosine Yellowish-(YS)/metabolism , Eosine Yellowish-(YS)/pharmacology , Hematoxylin/metabolism , Hematoxylin/pharmacology , Hippocampus/metabolism , Homovanillic Acid/metabolism , Homovanillic Acid/pharmacology , Hydroxyindoleacetic Acid/metabolism , Methoxyhydroxyphenylglycol/analogs & derivatives , Methoxyhydroxyphenylglycol/metabolism , Methoxyhydroxyphenylglycol/pharmacology , Monoamine Oxidase/metabolism , Neurotransmitter Agents/metabolism , Norepinephrine/metabolism , Norepinephrine/pharmacology , Plant Extracts , Rats , Rehmannia/chemistry , Serotonin/metabolism , Serotonin Plasma Membrane Transport Proteins/metabolism , Serotonin Plasma Membrane Transport Proteins/pharmacology , Stress, Psychological/drug therapy , Stress, Psychological/metabolism , Tandem Mass Spectrometry , Tryptophan Hydroxylase/metabolismABSTRACT
Emodin nanostructured lipid carriers(ED-NLC) were prepared and their quality was evaluated in vitro. Based on the results of single-factor experiments, the ED-NLC formulation was optimized by Box-Behnken response surface method with the dosages of emodin, isopropyl myristate and poloxamer 188 as factors and the nanoparticle size, encapsulation efficiency and drug loading as evaluation indexes. Then the evaluation was performed on the morphology, size and in vitro release of the nanoparticles prepared by emulsification-ultrasonic dispersion method in line with the optimal formulation, i.e., 3.27 mg emodin, 148.68 mg isopropyl myristate and 173.48 mg poloxamer 188. Under a transmission electron microscope(TEM), ED-NLC were spherical and their particle size distribution was uniform. The particle size of ED-NLC was(97.02±1.55) nm, the polymer dispersion index 0.21±0.01, the zeta potential(-38.96±0.65) mV, the encapsulation efficiency 90.41%±0.56% and the drug loading 1.55%±0.01%. The results of differential scanning calorimeter(DSC) indicated that emodin may be encapsulated into the nanostructured lipid carriers in molecular or amorphous form. In vitro drug release had obvious characteristics of slow release, which accorded with the first-order drug release equation. The fitting model of Box-Behnken response surface methodology was proved accurate and reliable. The optimal formulation-based ED-NLC featured concentrated particle size distribution and high encapsulation efficiency, which laid a foundation for the follow-up study of ED-NLC in vivo.
Subject(s)
Emodin , Nanostructures , Drug Carriers , Follow-Up Studies , LipidsABSTRACT
This study aimed to explore the anti-depressant components of Rehmanniae Radix and its action mechanism based on network pharmacology combined with molecular docking. The main components of Rehmanniae Radix were identified by ultra-high performance liquid chromatography-quadrupole/Orbitrap high resolution mass spectrometry(UPLC-Q-Orbitrap HRMS), and the related targets were predicted using SwissTargetPrediction. Following the collection of depression-related targets from GeneCards, OMIM and TTD, a protein-protein interaction(PPI) network was constructed using STRING. GO and KEGG pathway enrichment analysis was performed by Metascape. Cytoscape 3.7.2 was used to construct the networks of "components-targets-disease" and "components-targets-pathways", based on which the key targets and their corresponding components were obtained and then preliminarily verified by molecular docking. Rehmanniae Radix contained 85 components including iridoids, ionones, and phenylethanoid glycosides. The results of network analysis showed that the main anti-depressant components of Rehmanniae Radix were catalpol, melittoside, genameside C, gardoside, 6-O-p-coumaroyl ajugol, genipin-1-gentiobioside, jiocarotenoside A1, neo-rehmannioside, rehmannioside C, jionoside C, jionoside D, verbascoside, rehmannioside, cistanoside F, and leucosceptoside A, corresponding to the following 16 core anti-depression targets: AKT1, ALB, IL6, APP, MAPK1, CXCL8, VEGFA, TNF, HSP90 AA1, SIRT1, CNR1, CTNNB1, OPRM1, DRD2, ESR1, and SLC6 A4. As revealed by molecular docking, hydrogen bonding and hydrophobicity might be the main action forms. The key anti-depression targets of Rehmanniae Radix were concentrated in 24 signaling pathways, including neuroactive ligand-receptor interaction, neurodegenerative disease-multiple diseases pathway, phosphatidylinositol 3-kinase/protein kinase B pathway, serotonergic synapse, and Alzheimer's disease.
Subject(s)
Drugs, Chinese Herbal , Neurodegenerative Diseases , Drugs, Chinese Herbal/pharmacology , Humans , Molecular Docking Simulation , Network Pharmacology , Plant Extracts , RehmanniaABSTRACT
A rapid and sensitive method was developed and validated for the quantitative determination of xanthopurpurin (XPP) in rat plasma using ultra-performance liquid chromatography-electrospray ionization-Orbitrap mass spectrometry. XPP inhibits IgE production and prevents peanut-induced anaphylaxis. The XPP and emodin (internal standard) were determined in negative ion mode with m/z 239.0350 â 211.0400 and 269.0455 â 241.0507, respectively. The separation process was achieved using an ACQUITY UPLC HSS T3 column with acetonitrile and 0.1% formic acid in water (85:15). The linear range was 0.5-100 ng/mL, and the correlation coefficient (r2 ) was > 0.993. The inter-day and intra-day precision was within an acceptable range of 15%. The extraction recovery and matrix effect were 78.9-87.2% and 94.3-98.5%, respectively. Under different conditions, the XPP was stable in the range of 5.6-10.6%. This method was successfully applied to study the pharmacokinetics of XPP with an oral dose of 10.0 mg/kg and intravenous dose of 2.0 mg/kg in rats. The absolute oral bioavailability of XPP was 4.6%.
Subject(s)
Anthraquinones/blood , Anthraquinones/pharmacokinetics , Chromatography, High Pressure Liquid/methods , Spectrometry, Mass, Electrospray Ionization/methods , Animals , Anthraquinones/chemistry , Drugs, Chinese Herbal/chemistry , Emodin , Linear Models , Male , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Rubia/chemistry , Sensitivity and SpecificityABSTRACT
Modern research showed that components in the dried leaf of Cyclocarya paliurus. had various biological activities. The current quality control research was focused on content determination of polysaccharides and flavonoids, while there were less research on quantitative analysis of terpenes and phenolic acids. In this paper, the contents of 16 components of 3 kinds in C. paliurus leaf were determined by UPLC-QE-Orbitrap-MS. The results were as following: good linear relationship of 16 analytes existed within the studied concentration rages (R²>0.996), and RSDs were of <3.0% in the precision test and replicate test, with the average recovery rates 95.20%-104.4%, respectively. The results indicatod that the method is simple and accurate, which can be used for the comprehensive quality evaluation of C. paliurus leaf. The established method was applied to determine the contents of 12 batches of C. paliurus leaf from different areas, and the 16 analvtes contents in the samples could be different from several times to dozens times, which indicated that there might be significant quality difference in C. paliurus leaf from different areas.
Subject(s)
Flavonoids/analysis , Juglandaceae/chemistry , Plant Leaves/chemistry , Polysaccharides/analysis , Phytochemicals/analysisABSTRACT
The ability of cationic liposomes composed of DC-Chol and cholesterol to carry pDNA into 293 T cells was investigated. Lipoplexes formed between DC-Chol/cholesterol liposomes and pDNA (encoding green fluorescent protein, GFP) were analyzed in terms of morphology observation, turbidity determination, particle size and zeta potential measurement, differential scanning calorimetry (DSC), gel retardation assay, cytotoxicity analysis in 293 T cells and transfection efficiency. The results showed that liposome preparation at or above 66.7 mol% cholesterol in formulation exhibited a calorimetric transition caused by anhydrous cholesterol domain at about 41°C. In comparison with the control, DOPE-containing liposomes, DC-Chol/cholesterol carriers showed more stable particle size, lower turbidity, higher activity for transfecting cells in the presence of high concentration serum (50% FBS), primarily due to the neutral domain formation by increasing mole ratios of cholesterol in formulation, as well as relatively lower cytotoxicity. Based on the results, it is suggested that incorporating high contents of cholesterol might be a potentially applicable method for various kinds of cationic lipids to obtain the gene carriers with high capability for in vivo transfection.
Subject(s)
Cholesterol/analogs & derivatives , Liposomes/chemistry , Transfection/methods , Calorimetry, Differential Scanning , Cations , Cell Line , Cell Survival/drug effects , Chemistry, Pharmaceutical , Cholesterol/chemistry , DNA/chemistry , DNA/genetics , Drug Delivery Systems , Electrochemistry , Humans , Light , Nanoparticles , Nephelometry and Turbidimetry , Particle Size , Scattering, Radiation , T-LymphocytesABSTRACT
Glucuronidation is an important pathway in the elimination of salvianolic acid A (Sal A); however the mechanism of UDP-glucuronosyltransferases (UGTs) in this process remains to be investigated. In this study, the kinetics of Sal A glucuronidation by pooled human liver microsomes (HLMs), pooled human intestinal microsomes (HIMs) and 12 recombinant UGT isozymes were investigated. The glucuronidation of Sal A can be shown both in HLMs and HIMs with K(m) values of 39.84 ± 3.76 and 54.04 ± 4.36 µM, respectively. Among the 12 human UGTs investigated, UGT1A1 and UGT1A9 were the major isoforms that catalyzed the glucuronidation of Sal A (K(m) values of 29.72 ± 2.20 and 24.40 ± 2.60 µM). UGT1A9 showed the highest affinity of Sal A glucuronidation. Furthermore, a significant correlation between Sal A glucuronidation and propofol glucuronidation (a typical UGT1A9 substrate) was observed. The chemical inhibition study showed that the IC(50) for phenylbutazone inhibition of Sal A glucuronidation was 50.3 ± 4.3 and 39.4 ± 2.9 µM by HLMs and UGT1A9, respectively. Mefenamic acid inhibited Sal A glucuronidation in UGT1A1 and HLMs with IC(50) values of >200 and 12.4 ± 2.2 µM, respectively.
Subject(s)
Caffeic Acids/pharmacokinetics , Glucuronosyltransferase/metabolism , Lactates/pharmacokinetics , Caffeic Acids/metabolism , Glucuronidase/metabolism , Glucuronosyltransferase/antagonists & inhibitors , Humans , Hydrolysis/drug effects , Intestinal Mucosa/metabolism , Intestines/drug effects , Intestines/enzymology , Isoenzymes/metabolism , Kinetics , Lactates/metabolism , Mefenamic Acid/pharmacology , Microsomes/drug effects , Microsomes/enzymology , Microsomes/metabolism , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Microsomes, Liver/metabolism , Propofol/metabolism , Propofol/pharmacokinetics , Statistics as Topic , UDP-Glucuronosyltransferase 1A9ABSTRACT
Three most commonly used preparative methods, dry-film, reverse phase evaporation and ethanol injection were employed to prepare cationic liposomes composed of DC-Chol and DOPE, respectively. The resulting samples were contrasted through morphology observation, particle size and zeta potential analysis. Sephadex filtration method with high selectivity was developed to determine the encapsulation efficiency of plasmid DNA-loaded cationic vectors, on this basis, cationic liposomes formulation was further optimized by applying Box Behnken design with encapsulation efficiency as evaluation index. The results showed that liposomes prepared by dry-film method were of best quality and stability, moreover, the optimum formulation of cationic liposomes and optimal value of each influencing factors were quantitatively obtained, measured value was highly consistent with predicted results. These findings preliminarily clarified the effect of preparative methods on performance of cationic liposome, as well as formulation factors on encapsulation efficiency, and will provide important methodological reference for further study of liposomes carriers for gene delivery.
Subject(s)
Cholesterol/analogs & derivatives , DNA/administration & dosage , Gene Transfer Techniques , Phosphatidylethanolamines/chemistry , Cations , Chemistry, Pharmaceutical/methods , Cholesterol/chemistry , Dextrans , Ethanol/chemistry , Filtration , Liposomes , Particle Size , PlasmidsABSTRACT
A tritium((3)H)-labeling method with high specificity was established to investigate the pharmacokinetics and disposition of the calf thymus DNA (ctDNA) in rats. The plasma pharmacokinetics, tissue distribution, mass balance and excretion were characterized in SD rats, respectively. Rats were injected i.v. with radiolabeled ctDNA with the dose of 40µCi/kg in each independent experiment. (3)H-labeled ctDNA was eliminated rapidly in plasma, with the half-life estimated from 9 to 13h and preferentially accumulated in liver and lung, its concentration in all the tissues investigated decreased to very low level after 24h. ctDNA exhibited 80.8% accumulative recovery, excretion of radiolabel in urine and bile was nearly complete by 72h, which shown as the main excretion pathways, and the total recovery of excretion reached 77.9% within three days. In conclusion, ctDNA was rapidly eliminated in plasma and would not accumulate in tissues, parent ctDNA and its radioactive metabolites can be recovered almost completely in schedule time. All the results indicated that the in vitro use of ctDNA is safe and will not bring out potential risk.
Subject(s)
DNA/pharmacokinetics , Tritium/analysis , Animals , Bile/chemistry , DNA/urine , Feces/chemistry , Female , Half-Life , Male , Rats , Rats, Sprague-Dawley , Tissue DistributionABSTRACT
Dicycloplatin, as a new antitumor supramolecule, was considered to have higher solubility and higher stability compared with carboplatin. The aim of the present study was to evaluate the pharmacokinetic characteristics of platinum originating from dicycloplatin. A rapid, sensitive, and specific method with inductively coupled plasma mass spectrometry (ICP-MS) has been developed for the determination of platinum in bio-samples. The study was performed in male rats and dogs at a single dose of 10 and 5 mg kg(-1) separately by intravenous injection. Pharmacokinetic parameters were calculated by non-compartmental method, and the dose of platinum was used in the calculation of these parameters. Results showed that plasma concentrations of platinum began to decrease rapidly initially but decline slowly with a long terminal phase. The mean half-life was 27.39 and 100.98 and clearance was 0.77 and 0.08 L/h/kg for rats and dogs separately. Tissue distribution showed that platinum originating from dicycloplatin had a certain distribution in testis and prostate. Plasma protein binding proportion of platinum was increased with time. In conclusion, this research investigated the pharmacokinetic characteristics including plasma kinetics, tissue distribution, and plasma protein binding of platinum originating from dicycloplatin in rats and dogs in detail for the first time by ICP-MS.
Subject(s)
Antineoplastic Agents/pharmacokinetics , Glutamates/pharmacokinetics , Mass Spectrometry/methods , Organoplatinum Compounds/pharmacokinetics , Platinum/pharmacokinetics , Animals , Antineoplastic Agents/administration & dosage , Carboplatin/pharmacology , Dogs , Drug Combinations , Drug Screening Assays, Antitumor/methods , Glutamates/administration & dosage , Half-Life , Injections, Intravenous , Male , Organoplatinum Compounds/administration & dosage , Platinum/blood , Prostate/metabolism , Protein Binding , Rats , Rats, Sprague-Dawley , Sensitivity and Specificity , Testis/metabolism , Time Factors , Tissue DistributionABSTRACT
This article studied the possible effect of rifampicin (RIF), an inhibitor of organic anion transporting polypeptide (Oatp), on the pharmacokinetics of salvianolic acid B (SAB) in rats. Rifampicin was administered intravenously 15 min prior to SAB (5 mg/kg) in rats at doses of 0, 5.0, 10.0 and 20.0 mg/kg, respectively. The concentrations of SAB in plasma and bile were determined using a Shimadzu HPLC system coupled to a LC-MS-2010EV mass spectrometer. Compared with the control group, the AUC(0-t) and C(max) values of SAB were increased significantly, while the CL(total) and CL(bile) were decreased significantly. These results suggested that pretreatment with rifampicin prior to SAB administration could decrease significantly the total and bile elimination of SAB and alter its pharmacokinetic profiles. The influence of rifampicin on the pharmacokinetics of SAB may be attributed to the inhibition of Oatp-mediated influx.
Subject(s)
Benzofurans/pharmacokinetics , Bile/metabolism , Enzyme Inhibitors/pharmacology , Organic Anion Transporters/antagonists & inhibitors , Plant Extracts/pharmacokinetics , Rifampin/pharmacology , Salvia miltiorrhiza/chemistry , Animals , Area Under Curve , Benzofurans/blood , Benzofurans/metabolism , Biological Transport/drug effects , Chromatography, High Pressure Liquid , Chromatography, Liquid , Herb-Drug Interactions , Male , Mass Spectrometry , Plant Extracts/blood , Plant Extracts/metabolism , Rats , Rats, Sprague-DawleyABSTRACT
Salvianolic acid A, salvianolic acid B, danshensu, protocatechuic aldehyde, rosmarinic acid and lithospermic acid are the six major active constituents in Danshen injection. In this study, a rapid, sensitive and specific liquid chromatographic-electrospray ionization-mass spectrometry method for the simultaneous quantitative determination of these compounds in rat plasma was developed. After a single step of liquid-liquid extraction with ethyl acetate, they were eluted by a Hypersil C18 column (5 µm, i.d. 4.6 × 200 mm) within 4 min with a mobile phase consisting of acetonitrile and 0.1% formic acid water solution (35:65, v/v). The assay was linear in the concentration range of 0.05-10 µg mL(-1). Absolute recoveries were above 60%. The precisions and accuracies determined within three consecutive days were within acceptable limits. The method was successfully applied to a pharmacokinetic study in rats after an intravenous administration of Danshen injection.
Subject(s)
Drugs, Chinese Herbal/administration & dosage , Drugs, Chinese Herbal/pharmacokinetics , Liquid-Liquid Extraction/methods , Mass Spectrometry/methods , Plant Preparations/administration & dosage , Salvia miltiorrhiza/chemistry , Spectrometry, Mass, Electrospray Ionization/methods , Animals , Benzaldehydes/blood , Benzaldehydes/pharmacokinetics , Benzofurans/blood , Benzofurans/pharmacokinetics , Caffeic Acids/blood , Caffeic Acids/pharmacokinetics , Catechols/blood , Catechols/pharmacokinetics , Chromatography, High Pressure Liquid/methods , Chromatography, Liquid/methods , Cinnamates/blood , Cinnamates/pharmacokinetics , Depsides/blood , Depsides/pharmacokinetics , Drug Stability , Drugs, Chinese Herbal/chemistry , Injections, Intravenous , Lactates/blood , Lactates/pharmacokinetics , Male , Plant Preparations/blood , Plant Preparations/chemistry , Rats , Reference Standards , Sensitivity and Specificity , Rosmarinic AcidABSTRACT
Wogonin, derived from the root of Scutellaria baicalensis, is a popular herb for its anticancer, anti-inflammatory, neuroprotective and anti-convulsant effects. The purpose of this study was to investigate the effect of wogonin on human hepatic cytochrome P450s (CYP450s) in vitro. Isoform-specific substrate probes of CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 were incubated in human liver microsomes with or without wogonin. IC(50) and K (i) values were estimated and the types of inhibition were determined. Wogonin was a potent, competitive inhibitor of CYP1A2 (K (i) = 0.24 µM), and a weak inhibitor of CYP2C19 (IC(50) = 101.10 µM), but was not able to inhibit CYP2C9, CYP2D6, CYP2E1 and CYP3A4 (IC(50) > 200 µM). Wogonin could inhibit the activity of CYP1A2 and CYP2C19 with varying potency, while it is a strong inhibitor of CYP1A2. These findings suggested that it was necessary to study the potential pharmacokinetic drug interaction in vivo.
Subject(s)
Biocatalysis , Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Flavanones/pharmacology , Microsomes, Liver/enzymology , Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors , Cytochrome P-450 CYP1A2 Inhibitors , Cytochrome P-450 CYP2C19 , Cytochrome P-450 Enzyme System/metabolism , Drug Interactions , Humans , Microsomes, Liver/drug effectsABSTRACT
A simple, robust, and sensitive high-performance liquid chromatography/mass spectrometric method was developed for the determination of corosolic acid, a potential anti-diabetes substance, in rat plasma using glycyrrhetinic acid as the internal standard (IS). This method involved a liquid-liquid extraction with acetic ether and a subsequent analysis performed on an LC-MS system which contained an electrospray ionization interface. Chromatographic separation was performed using an ODS column, and the mobile phase was composed of methanol and 5 mmol/L ammonium acetate (88â:â12, v/v). Good linearity was observed over the concentration range of 20-10â,000 ng/mL with a correlation coefficient (r² ≥ 0.995. The method was proved to be accurate and reliable and was applied to a pharmacokinetic study in the rat following intragastric and intravenous administration of corosolic acid.
Subject(s)
Chromatography, High Pressure Liquid/methods , Hypoglycemic Agents/blood , Hypoglycemic Agents/pharmacokinetics , Triterpenes/blood , Triterpenes/pharmacokinetics , Administration, Oral , Animals , Biological Availability , Calibration , Chromatography, High Pressure Liquid/standards , Drug Stability , Glycyrrhetinic Acid/analysis , Injections, Intravenous , Liquid-Liquid Extraction , Plasma , Quality Control , Rats , Rats, Sprague-Dawley , Reference Standards , Reproducibility of Results , Sensitivity and Specificity , Spectrometry, Mass, Electrospray Ionization , Time FactorsABSTRACT
PURPOSE: Repaglinide is commonly used in the treatment of patients with type 2 diabetes mellitus to reduce postprandial hyperglycemia. The objective of this research was to study the effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. METHODS: A total of 22 healthy young male participants were recruited from a pool of pharmacogenetically characterized participants genotyped for SLCO1B1, CYP3A4, and CYP2C8 SNPs by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Volunteers with CYP2C8*3 and CYP3A4*4 alleles were excluded from the clinical study. Then selected volunteers took part in the clinical pharmacokinetic study, receiving 2 mg repaglinide. RESULTS: Healthy participants with SLCO1B1*1A/*1B or *1A/*1A genotype and SLCO1B1 *15/*1A or *5/*1A genotype had significantly higher AUC(0-∞) than participants with SLCO1B1*1B/*1B genotype, with the former showing an increase over the latter of 39.81 and 42.09%, respectively (P = 0.028, 0.032). The clearance in the former two genotype groups was significantly attenuated (by 27.39 and 28.55%, respectively) compared with individuals with SLCO1B1*1B/*1B genotype (P = 0.015, 0.019). No significant differences in blood glucose-lowering effect were observed among three genotype groups. CONCLUSIONS: SLCO1B1*1B/*1B genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC(0-∞) and increased clearance of repaglinide. Moreover, this polymorphism of SLCO1B1 has significant influence on the pharmacokinetics of repaglinide, but no effects on its pharmacodynamics.
Subject(s)
Carbamates/pharmacokinetics , Hypoglycemic Agents/pharmacokinetics , Organic Anion Transporters/genetics , Piperidines/pharmacokinetics , Polymorphism, Single Nucleotide , Adult , Area Under Curve , Aryl Hydrocarbon Hydroxylases/genetics , Asian People/genetics , Carbamates/administration & dosage , Cytochrome P-450 CYP2C8 , Cytochrome P-450 CYP3A/genetics , Genotype , Humans , Hypoglycemic Agents/administration & dosage , Liver-Specific Organic Anion Transporter 1 , Male , Piperidines/administration & dosage , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Prospective Studies , Young AdultABSTRACT
A simple, specific, and precise liquid chromatographic-electrospray ionization mass spectrometric (LC-ESI-MS) method has been developed for determination of nimodipine concentration in human plasma. The method involves the addition of 200 microL of saturated sodium bicarbonate (NaHCO(3)) solution to plasma to improve the extraction recovery, liquid-liquid extraction of nimodipine from plasma samples with anhydrous diethyl ether, simple reversed-phase chromatography, and ESI mass spectrometric detection in negative ion selected ion monitoring mode (SIM) using target [M-] ions at m/z 417 and m/z 359 for nimodipine and nitrendipine (internal standard, IS), respectively. A complete analytical run was achieved within 3.5 min. The limit of quantification was 0.5 ng/mL. The method was validated within a linear range of 0.5-100 ng/mL. The correlation coefficient for the calibration regression line was 0.9995 or better. Intra- and inter-batch accuracy and precision were acceptable. Analyte was stable in a battery of stability studies. The method has been successfully used in a bioequivalence study.
Subject(s)
Calcium Channel Blockers/blood , Chromatography, High Pressure Liquid/methods , Nimodipine/blood , Spectrometry, Mass, Electrospray Ionization/methods , Calcium Channel Blockers/pharmacokinetics , Calibration , Humans , Limit of Detection , Nimodipine/pharmacokinetics , Therapeutic EquivalencyABSTRACT
BACKGROUND: Considering the chronic and repeated nature of salmon calcitonin (sCT) therapy, the oral route is a preferred route of administration. But, the oral bioavailability of sCT is very low due to enzymatic degradation and poor permeation across intestinal epithelial cells. It was the aim of this study to investigate the pharmacodynamic (PD), pharmacokinetic (PK), and mucosal injury characteristic of sCT oral delivery system. METHOD: In this study, PD experiments were performed to find a suitable releasing region of sCT, an effect absorption enhancer, and an optimal mass ratio of sCT/enhancer. In addition, the PK experiments were designed to validate the absorption enhancement of this oral delivery system. Histopathological evaluations on the intestinal mucosa were carried out to assess any potential toxicity of the absorption enhancer. RESULTS: Through the PD research, we determined that oral sCT enteric-coated capsules containing sCT and citric acid (CA) with a ratio of 1:20 may be an adaptable delivery. PK study further proved that the oral absorption of sCT was enhanced from this delivery system. Finally, no damage on intestinal mucosa was observed when rats received the delivery system containing CA for up to 7 days. CONCLUSION: These results suggested that enteric-coated capsules with a certain amount of CA might give enhanced oral delivery of peptide drugs like sCT.